Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of the Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center, shared a post on X about a recent paper by Solange Peters et al. published in Journal of Thoracic Oncology:
“Long-term outcomes of Using nivolumab plus ipilimumab as a treatment to patients with metastatic NSCLC and tumor PD-L1 lower than 1% provides a long-term, durable clinical benefit, with or without chemotherapy, according to Peters S et al. via Journal of Thoracic Oncology.”
Authors: Solange Peters, Luis Paz-Ares, Martin Reck, Diederik Grootendorst, Suresh Ramalingam et al.
More posts featuring Estela Rodriguez.